{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T07:54:07Z","timestamp":1786866847373,"version":"build-2736575974"},"reference-count":83,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011665","name":"Deanship of Scientific Research, King Saud University","doi-asserted-by":"publisher","award":["1435-024"],"award-info":[{"award-number":["1435-024"]}],"id":[{"id":"10.13039\/501100011665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032135","name":"Sanofi Saudi Arabia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100032135","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005565","name":"Johnson & Johnson Innovative Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.clml.2025.06.005","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T11:18:59Z","timestamp":1749035939000},"page":"851-862.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Definition, Diagnosis, Risk Stratification and Management of Newly Diagnosed Multiple Myeloma: The Saudi Myeloma Working Group Guidelines"],"prefix":"10.1016","volume":"25","author":[{"given":"Ghazi S.","family":"Alotaibi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah S. Al","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Alhejazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majed","family":"Alahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibraheem","family":"Motabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad Z.","family":"Alsharif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Alamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Abduljalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran","family":"Tailor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Marei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed S.","family":"Barefah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansour","family":"Aljabry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saud","family":"Alhayli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binyam","family":"Usman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Hanbali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Alabdulwahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ihab","family":"ElHemaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatem Mahmoud","family":"Alahwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enas","family":"Mutahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1711-7013","authenticated-orcid":false,"given":"Ahmad","family":"Alsaeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clml.2025.06.005_bib0001","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1186\/s12885-021-08280-y","article-title":"Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019","volume":"21","author":"Zhou","year":"2021","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.clml.2025.06.005_bib0002","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","article-title":"Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study","volume":"26","author":"Kumar","year":"2012","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.clml.2025.06.005_bib0003","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global Burden of Multiple Myeloma: a systematic analysis for the global burden of disease study 2016","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.clml.2025.06.005_bib0004","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","article-title":"Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.clml.2025.06.005_bib0005","article-title":"A study on renal failure management in patients diagnosed with multiple myeloma","volume":"15","author":"Almuhaysen","year":"2023","journal-title":"Cureus"},{"issue":"12","key":"10.1016\/j.clml.2025.06.005_bib0006","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.bbmt.2020.08.018","article-title":"The global state of hematopoietic cell transplantation for multiple myeloma: an analysis of the worldwide network of blood and marrow transplantation database and the global burden of disease study","volume":"26","author":"Cowan","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.clml.2025.06.005_bib0007","doi-asserted-by":"crossref","first-page":"198","DOI":"10.5144\/0256-4947.2021.198","article-title":"Outcomes of autologous stem cell transplantation for multiple myeloma in Saudi Arabia","volume":"41","author":"Abdrabou","year":"2021","journal-title":"Ann Saudi Med"},{"issue":"1","key":"10.1016\/j.clml.2025.06.005_bib0008","doi-asserted-by":"crossref","first-page":"67","DOI":"10.46989\/001c.92555","article-title":"Epidemiology, treatment trends, and outcomes of multiple myeloma in the Middle East and Africa: a systematic review","volume":"6","author":"Mattar","year":"2024","journal-title":"Clin Hematol Int"},{"issue":"11","key":"10.1016\/j.clml.2025.06.005_bib0009","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.24911\/IJMDC.51-1667999896","article-title":"Multiple myeloma in Saudi Arabia: a comprehensive literature review","volume":"7","author":"AlSharif","year":"2023","journal-title":"Int J Med Develop Count"},{"issue":"2","key":"10.1016\/j.clml.2025.06.005_bib0010","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4103\/joah.joah_62_18","article-title":"Multiple myeloma in Saudi Arabia: consensus of the Saudi lymphoma\/myeloma group","volume":"10","author":"Alaskar","year":"2019","journal-title":"J Appl Hematol"},{"key":"10.1016\/j.clml.2025.06.005_bib0011","doi-asserted-by":"crossref","unstructured":"Wahed A., Dasgupta A. Application of flow cytometry in the diagnosis of hematological disorders. Hematology and Coagulation. Elsevier; 2015:133\u2013145. Chapter 8 https:\/\/doi.org\/10.1016\/B978-0-12-800241-4.00008-5 Accessed Feb 25-2025.","DOI":"10.1016\/B978-0-12-800241-4.00008-5"},{"key":"10.1016\/j.clml.2025.06.005_bib0012","unstructured":"Overview of plasma cell disorders - Hematology and oncology - MSD manual professional edition. Available at: https:\/\/www.msdmanuals.com\/professional\/hematology-and-oncology\/plasma-cell-disorders\/overview-of-plasma-cell-disorders. Accessed February 2, 2025."},{"issue":"12","key":"10.1016\/j.clml.2025.06.005_bib0013","doi-asserted-by":"crossref","first-page":"177","DOI":"10.7326\/AITC202212200","article-title":"Monoclonal gammopathy of undetermined significance","volume":"175","author":"Gonsalves","year":"2022","journal-title":"Ann Intern Med"},{"issue":"20","key":"10.1016\/j.clml.2025.06.005_bib0014","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/blood-2014-09-568899","article-title":"Smoldering multiple myeloma","volume":"125","author":"Rajkumar","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.06.005_bib0015","unstructured":"Kumar SK, Anderson LD, Baljevic M, et al. NCCN Guidelines Version 3.2024 Multiple Myeloma NCCN Guidelines Index Table of Contents Discussion NCCN Guidelines Panel Disclosures \u03be Bone marrow transplantation \u2021 Hematology \u00de Internal medicine \u2020 Medical oncology \u00a5 Patient advocacy \u00a7 Radiation oncology * Discussion section writing committee Continue. 2024. Available at: https:\/\/www.nccn.org\/home\/member. Accessed February 2, 2025."},{"issue":"4","key":"10.1016\/j.clml.2025.06.005_bib0016","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2991\/chi.k.200706.002","article-title":"Plasma Cell leukemia \u2013 facts and controversies: more questions than answers?","volume":"2","author":"Suska","year":"2020","journal-title":"Clin Hematol Int"},{"issue":"4","key":"10.1016\/j.clml.2025.06.005_bib0017","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/leu.2012.336","article-title":"PLASMA CELL LEUKEMIA: Consensus Statement on Diagnostic Requirements, Response Criteria, and Treatment Recommendations by the International Myeloma Working Group (IMWG)","volume":"27","author":"Larrea","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2025.06.005_bib0018","unstructured":"Ferlay J, Ervik M, Lam F, et al. Global cancer observatory: cancer today. lyon, france: International agency for research on cancer. Available at: https:\/\/gco.iarc.who.int\/today, Accessed: April 11, 2024. 2024."},{"issue":"9","key":"10.1016\/j.clml.2025.06.005_bib0019","first-page":"2437","article-title":"Cancer Incidence in Saudi Arabia: 2012 data from the Saudi cancer registry","volume":"18","author":"Bazarbashi","year":"2017","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.clml.2025.06.005_bib0020","unstructured":"Cancer Incidence Report - Saudi Arabia. Accessed: April 11, 2024. Available from: https:\/\/shc.gov.sa\/Arabic\/NCC\/Activities\/Pages\/AnnualReports.aspx."},{"issue":"4","key":"10.1016\/j.clml.2025.06.005_bib0021","doi-asserted-by":"crossref","first-page":"198","DOI":"10.5144\/0256-4947.2021.198","article-title":"Outcomes of autologous stem cell transplantation for multiple myeloma in Saudi Arabia","volume":"41","author":"Abdrabou","year":"2021","journal-title":"Ann Saudi Med"},{"issue":"6","key":"10.1016\/j.clml.2025.06.005_bib0022","doi-asserted-by":"crossref","first-page":"642","DOI":"10.5144\/0256-4947.1991.642","article-title":"Multiple myeloma: a review of 92 cases at King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia","volume":"11","author":"Khalil","year":"1991","journal-title":"Ann Saudi Med"},{"issue":"12","key":"10.1016\/j.clml.2025.06.005_bib0023","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol. Lancet Publishing Group"},{"issue":"21","key":"10.1016\/j.clml.2025.06.005_bib0024","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14215247","article-title":"Monoclonal gammopathies of clinical significance: a critical appraisal","volume":"14","author":"R\u00edos-Tamayo","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1D","key":"10.1016\/j.clml.2025.06.005_bib0025","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2024.0001","article-title":"Waldenstr\u00f6m Macroglobulinemia\/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Kumar","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"26","key":"10.1016\/j.clml.2025.06.005_bib0026","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: A report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.clml.2025.06.005_bib0027","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clml.2025.06.005_bib0028","doi-asserted-by":"crossref","first-page":"933","DOI":"10.4065\/mcp.2010.0337","article-title":"Prevalence of monoclonal gammopathy of undetermined significance: a systematic review","volume":"85","author":"Wadhera","year":"2010","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"10.1016\/j.clml.2025.06.005_bib0029","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International myeloma working group risk stratification model for smoldering multiple myeloma (SMM)","volume":"10","author":"Mateos","year":"2020","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1016\/j.clml.2025.06.005_bib0030","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.clml.2025.06.005_bib0031","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"P\u00e9rez-Persona","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2025.06.005_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria","volume":"8","author":"Lakshman","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2025.06.005_bib0033","doi-asserted-by":"crossref","unstructured":"Sonneveld P, Avet-Loiseau H, Lonial S, et al. Perspectives treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma working group. 2016; doi: 10.1182\/blood-2016-01.","DOI":"10.1182\/blood-2016-01-631200"},{"issue":"4","key":"10.1016\/j.clml.2025.06.005_bib0034","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1365-2141.2010.08157.x","article-title":"Plasma cell leukaemia and other aggressive plasma cell malignancies","volume":"150","author":"Sher","year":"2010","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.clml.2025.06.005_bib0035","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2991\/chi.k.200706.002","article-title":"Plasma Cell Leukemia \u2013 Facts and Controversies: More Questions than Answers?","volume":"2","author":"Suska","year":"2020","journal-title":"Clin Hematol Int"},{"issue":"20","key":"10.1016\/j.clml.2025.06.005_bib0036","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1182\/blood-2014-11-568907","article-title":"New criteria for response assessment: role of minimal residual disease in multiple myeloma","volume":"125","author":"Paiva","year":"2015","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2025.06.005_bib0037","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous Transplantation and Maintenance Therapy in Multiple Myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.clml.2025.06.005_bib0038","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, Bortezomib, and Dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.clml.2025.06.005_bib0039","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.clml.2025.06.005_bib0040","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/jamaoncol.2017.4600","article-title":"Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction: a systematic review and meta-analysis","volume":"4","author":"Dhakal","year":"2018","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.clml.2025.06.005_bib0041","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/bmt.2016.174","article-title":"Autologous stem cell transplant for multiple myeloma patients 70 years or older","volume":"51","author":"Muchtar","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.clml.2025.06.005_bib0042","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern cooperative oncology group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clml.2025.06.005_bib0043","doi-asserted-by":"crossref","unstructured":"Altilio T., Otis-Green S., and Cagle J.G. (eds), The Oxford Textbook of Palliative Social Work, 2 ed. New York: Oxford Academic, 2022, https:\/\/doi.org\/10.1093\/med\/9780197537855.001.0001. Accessed June 24, 2025.","DOI":"10.1093\/med\/9780197537855.001.0001"},{"issue":"2","key":"10.1016\/j.clml.2025.06.005_bib0044","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1161\/01.STR.24.2.320","article-title":"Measuring quality of life in stroke","volume":"24","author":"Haan","year":"1993","journal-title":"Stroke"},{"issue":"4","key":"10.1016\/j.clml.2025.06.005_bib0045","first-page":"384","article-title":"Evaluating cancer patients for rehabilitation potential","volume":"155","author":"O\u2019Toole","year":"1991","journal-title":"Western J Med"},{"key":"10.1016\/j.clml.2025.06.005_bib0046","doi-asserted-by":"crossref","unstructured":"Paul B, Lipe B, Ocio EM, et al. Induction therapy for newly diagnosed multiple myeloma. https:\/\/doi.org\/101200\/EDBK_238527. 2019 Accessed: March 21, 2024;(39):e176\u2013e186.","DOI":"10.1200\/EDBK_238527"},{"issue":"4","key":"10.1016\/j.clml.2025.06.005_bib0047","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clml.2025.06.005_bib0048","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","volume":"9","author":"Goldschmidt","year":"2022","journal-title":"Lancet Haematol"},{"issue":"10068","key":"10.1016\/j.clml.2025.06.005_bib0049","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.clml.2025.06.005_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-020-0311-8","volume":"10","author":"Durie","year":"2020","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1016\/j.clml.2025.06.005_bib0082","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.06.005_bib0051","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.clml.2025.06.005_bib0052","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.mayocp.2020.06.060","article-title":"Clinical characteristics and outcomes of patients with primary plasma cell leukemia in the era of novel agent therapy","volume":"96","author":"Nandakumar","year":"2021","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"10.1016\/j.clml.2025.06.005_bib0053","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1016\/S1470-2045(23)00223-1","article-title":"Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group","volume":"24","author":"Dimopoulos","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2025.06.005_bib0054","first-page":"5","article-title":"MULTIPLE MYELOMA Myeloma Australia\u2019s Medical and Scientific Advisory Group (MSAG)","author":"Quach","year":"2022","journal-title":"Multiple Myeloma"},{"issue":"14","key":"10.1016\/j.clml.2025.06.005_bib0055","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.18.02096","article-title":"Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline","volume":"37","author":"Mikhael","year":"2019","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clml.2025.06.005_bib0056","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1038\/s41375-023-01936-7","article-title":"Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible\/with no immediate intent for autologous stem cell transplantation","volume":"37","author":"Ocio","year":"2023","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.clml.2025.06.005_bib0057","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"17_suppl","key":"10.1016\/j.clml.2025.06.005_bib0058","doi-asserted-by":"crossref","first-page":"LBA4","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA4","article-title":"Lenalidomide, bortezomib, and dexamethasone (RVd) \u00b1 autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM): The phase 3 DETERMINATION trial","volume":"40","author":"Richardson","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2025.06.005_bib0059","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/annonc\/mdw017","article-title":"Safe and prolonged survival with long-term exposure to pomalidomide in relapsed\/refractory myeloma","volume":"27","author":"Fouquet","year":"2016","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.clml.2025.06.005_bib0060","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/JCO.18.00685","article-title":"Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial","volume":"37","author":"Stadtmauer","year":"2019","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.06.005_bib0061","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1182\/blood-2018-99-112899","article-title":"Double vs single autologous stem cell transplantation for newly diagnosed multiple myeloma: long-term follow-up (10-Years) analysis of randomized phase 3 studies","volume":"132","author":"Cavo","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2025.06.005_bib0062","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.clml.2025.06.005_bib0063","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1470-2045(22)00693-3","article-title":"Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial","volume":"24","author":"Mina","year":"2023","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.clml.2025.06.005_bib0064","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","article-title":"Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial","volume":"10","author":"Voorhees","year":"2023","journal-title":"Lancet Haematol"},{"issue":"13","key":"10.1016\/j.clml.2025.06.005_bib0065","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2025.06.005_bib0066","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3324\/haematol.2016.162693","article-title":"A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients","volume":"102","author":"Engelhardt","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2025.06.005_bib0067","doi-asserted-by":"crossref","first-page":"e418","DOI":"10.1200\/EDBK_159009","article-title":"Updated Diagnostic Criteria and Staging System for Multiple Myeloma","volume":"35","author":"Rajkumar","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"11","key":"10.1016\/j.clml.2025.06.005_bib0068","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10068","key":"10.1016\/j.clml.2025.06.005_bib0069","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.clml.2025.06.005_bib0070","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clml.2025.06.005_bib0071","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.clml.2025.06.005_bib0072","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1365-2141.2008.07573.x","article-title":"Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline","volume":"144","author":"Richardson","year":"2009","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.clml.2025.06.005_bib0073","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S1470-2045(19)30506-6","article-title":"Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial","volume":"20","author":"Drayson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.clml.2025.06.005_bib0074","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/blood.2021011101","article-title":"Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA","volume":"139","author":"Cavo","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2025.06.005_bib0075","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3324\/haematol.2012.065698","article-title":"Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents","volume":"97","author":"Usmani","year":"2012","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.clml.2025.06.005_bib0076","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.3324\/haematol.2012.078519","article-title":"Extramedullary involvement in multiple myeloma","volume":"97","author":"Blad\u00e9","year":"2012","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.clml.2025.06.005_bib0077","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/leu.2011.29","article-title":"Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma","volume":"25","author":"Short","year":"2011","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.clml.2025.06.005_bib0078","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s00330-012-2600-5","article-title":"Comparative diagnostic performance of 18F-FDG PET\/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation","volume":"23","author":"Derlin","year":"2013","journal-title":"Eur Radiol"},{"issue":"4","key":"10.1016\/j.clml.2025.06.005_bib0079","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1600-0609.2010.01575.x","article-title":"Combining FDG-PET\/CT with laboratory data yields superior results for prediction of relapse in multiple myeloma","volume":"86","author":"Elliott","year":"2011","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1016\/j.clml.2025.06.005_bib0080","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s00259-015-3200-9","article-title":"Image interpretation criteria for FDG PET\/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe)","volume":"43","author":"Nanni","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1016\/j.clml.2025.06.005_bib0081","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.clml.2025.06.005_bib0084","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002101?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002101?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T01:11:15Z","timestamp":1763773875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025002101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":83,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2152265025002101"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.06.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Definition, Diagnosis, Risk Stratification and Management of Newly Diagnosed Multiple Myeloma: The Saudi Myeloma Working Group Guidelines","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}